<> "The repository administrator has not yet configured an RDF license."^^ . <> . . . "Endothelin receptor antagonist and airway dysfunction in pulmonary arterial hypertension"^^ . "Background: In idiopathic pulmonary arterial hypertension (IPAH), peripheral airway obstruction is frequent. This is partially attributed to the mediator dysbalance, particularly an excess of endothelin-1 (ET-1), to increased pulmonary vascular and airway tonus and to local inflammation. Bosentan (ET-1 receptor antagonist) improves pulmonary hemodynamics, exercise limitation, and disease severity in IPAH. We hypothesized that bosentan might affect airway obstruction. Methods: In 32 IPAH-patients (19 female, WHO functional class II (n = 10), III (n = 22); (data presented as mean ± standard deviation) pulmonary vascular resistance (11 ± 5 Wood units), lung function, 6 minute walk test (6-MWT; 364 ± 363.7 (range 179.0-627.0) m), systolic pulmonary artery pressure, sPAP, 79 ± 19 mmHg), and NT-proBNP serum levels (1427 ± 2162.7 (range 59.3-10342.0) ng/L) were measured at baseline, after 3 and 12 months of oral bosentan (125 mg twice per day). Results and Discussion: At baseline, maximal expiratory flow at 50 and 25% vital capacity were reduced to 65 ± 25 and 45 ± 24% predicted. Total lung capacity was 95.6 ± 12.5% predicted and residual volume was 109 ± 21.4% predicted. During 3 and 12 months of treatment, 6-MWT increased by 32 ± 19 and 53 ± 69 m, respectively; p < 0.01; whereas sPAP decreased by 7 ± 14 and 10 ± 19 mmHg, respectively; p < 0.05. NT-proBNP serum levels tended to be reduced by 123 ± 327 and by 529 ± 1942 ng/L; p = 0.11). There was no difference in expiratory flows or lung volumes during 3 and 12 months. Conclusion: This study gives first evidence in IPAH, that during long-term bosentan, improvement of hemodynamics, functional parameters or serum biomarker occur independently from persisting peripheral airway obstruction."^^ . "2009-12-30" . . "10" . "129" . . "BioMed Central"^^ . . . "Respiratory Research"^^ . . . "1465993X" . . . . . . . . . . . . . . . . . . . . . . . . . . "David"^^ . "Rohde"^^ . "David Rohde"^^ . . "F. Joachim"^^ . "Meyer"^^ . "F. Joachim Meyer"^^ . . "Thomas"^^ . "Bruckner"^^ . "Thomas Bruckner"^^ . . "Arthur"^^ . "Filusch"^^ . "Arthur Filusch"^^ . . "Hugo A."^^ . "Katus"^^ . "Hugo A. Katus"^^ . . "Mirko"^^ . "Völkers"^^ . "Mirko Völkers"^^ . . "Mathias Maximilian"^^ . "Borst"^^ . "Mathias Maximilian Borst"^^ . . "Annette S."^^ . "Droste"^^ . "Annette S. Droste"^^ . . . . . . "Endothelin receptor antagonist and airway dysfunction in pulmonary arterial hypertension (PDF)"^^ . . . "12931_2009_Article_843.pdf"^^ . . . "Endothelin receptor antagonist and airway dysfunction in pulmonary arterial hypertension (Other)"^^ . . . . . . "indexcodes.txt"^^ . . . "Endothelin receptor antagonist and airway dysfunction in pulmonary arterial hypertension (Other)"^^ . . . . . . "lightbox.jpg"^^ . . . "Endothelin receptor antagonist and airway dysfunction in pulmonary arterial hypertension (Other)"^^ . . . . . . "preview.jpg"^^ . . . "Endothelin receptor antagonist and airway dysfunction in pulmonary arterial hypertension (Other)"^^ . . . . . . "medium.jpg"^^ . . . "Endothelin receptor antagonist and airway dysfunction in pulmonary arterial hypertension (Other)"^^ . . . . . . "small.jpg"^^ . . "HTML Summary of #20193 \n\nEndothelin receptor antagonist and airway dysfunction in pulmonary arterial hypertension\n\n" . "text/html" . . . "610 Medizin"@de . "610 Medical sciences Medicine"@en . .